A Retrospective Study of Treatment Use in Metastatic Colorectal Cancer (mCRC) Based on French Hospital Discharge Database
Author(s)
Elise Arnee, PharmD1, Marie Ducros, Ms1, Oumaima Chibani, M.D. , MSc2, Benjamin Mazaleyrat, PharmD2.
1GERS-CEGEDIM France, Boulogne-Billancourt, France, 2AMGEN France, Courbevoie, France.
1GERS-CEGEDIM France, Boulogne-Billancourt, France, 2AMGEN France, Courbevoie, France.
OBJECTIVES: Recent data on metastatic Colorectal Cancer (mCRC) prevalence and use of biotherapies in France are lacking. This study aims to estimate the number of prevalent patients treated in care structure with mCRC diagnosis, identify treatments they received and assess their repartition across regions.
METHODS: A nationwide real-world retrospective study using hospital secondary data from the French Hospital Discharge Database (PMSI) included adult patients treated during a hospital stay with costly drug listed treatment indicated in mCRC in France in 2023. Region of hospitalization and type of care structure were identified. Primary tumor sidedness was collected following ICD-10 diagnosis code associated with the reason for hospital stay.
RESULTS: A total of 23,147 patients were included. The mean age was 68.1 years old (±11.7) and 58.6% were men. Regarding treatments, all treatment lines combined, 66.2% of patients received bevacizumab, 19.0% panitumumab, 15.6% cetuximab, and fewer patients received other treatments including, aflibercept (8.1%) and pembrolizumab (4.1%). Tumor sidedness was available for most patients (74.3%) with 59.7% diagnosed with a left colon tumor, and 23.7% with a right colon tumor. Patients were mainly treated with bevacizumab (71.7% and 66.1%) for right and left colon respectively. Panitumumab and cetuximab were respectively used in 24.9% and 18.3% of patients with left colon tumor and equally used (around 11%) in right colon tumor. One third of patients (36.3%) treated for mCRC were distributed across three regions: 14.6% in Ile-de France,11,4%, in Auvergne-Rhône-Alpes and 10,3% in Occitanie. Regarding care structure management, 49.6% were treated in public hospital, 32,4% in private hospital, and 17.9% in non-profit healthcare facilities.
CONCLUSIONS: This study provides a recent update of prevalence and region distribution of mCRC treated patients in France highlighting the predominant use of bevacizumab to treat mCRC in France irrespective of tumor sidedness and treatment line.
METHODS: A nationwide real-world retrospective study using hospital secondary data from the French Hospital Discharge Database (PMSI) included adult patients treated during a hospital stay with costly drug listed treatment indicated in mCRC in France in 2023. Region of hospitalization and type of care structure were identified. Primary tumor sidedness was collected following ICD-10 diagnosis code associated with the reason for hospital stay.
RESULTS: A total of 23,147 patients were included. The mean age was 68.1 years old (±11.7) and 58.6% were men. Regarding treatments, all treatment lines combined, 66.2% of patients received bevacizumab, 19.0% panitumumab, 15.6% cetuximab, and fewer patients received other treatments including, aflibercept (8.1%) and pembrolizumab (4.1%). Tumor sidedness was available for most patients (74.3%) with 59.7% diagnosed with a left colon tumor, and 23.7% with a right colon tumor. Patients were mainly treated with bevacizumab (71.7% and 66.1%) for right and left colon respectively. Panitumumab and cetuximab were respectively used in 24.9% and 18.3% of patients with left colon tumor and equally used (around 11%) in right colon tumor. One third of patients (36.3%) treated for mCRC were distributed across three regions: 14.6% in Ile-de France,11,4%, in Auvergne-Rhône-Alpes and 10,3% in Occitanie. Regarding care structure management, 49.6% were treated in public hospital, 32,4% in private hospital, and 17.9% in non-profit healthcare facilities.
CONCLUSIONS: This study provides a recent update of prevalence and region distribution of mCRC treated patients in France highlighting the predominant use of bevacizumab to treat mCRC in France irrespective of tumor sidedness and treatment line.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EPH8
Topic
Epidemiology & Public Health, Real World Data & Information Systems
Disease
Oncology